US71535D1063
© BusinessWire
11.12.2025
PSNL
LISTED
NASDAQ
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, in the journal Cell. The study, titled "Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk predic...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
PSNL
LISTED
NASDAQ
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at the Lotte New York Palace in New York, NY.
About Personalis, Inc.
At Personalis, we are transforming the active man...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
PSNL
LISTED
NASDAQ
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence in breast cancer patients. This milestone marks an important step forward in cancer surveillance, offering a powerful tool for doctors and breast ca...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
04.11.2025
PSNL
LISTED
NASDAQ
Personalis Reports Third Quarter 2025 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generat...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
21.10.2025
PSNL
LISTED
NASDAQ
Personalis to Announce Third Quarter 2025 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
PSNL
LISTED
NASDAQ
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that Personalis’ highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a useful tool in assessing the maintenance treatment respon...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
PSNL
LISTED
NASDAQ
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock option to purchase an aggregate of 440,000 shares of its common stock to Personalis’ new Senior Vice President, Chief Information Offi...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
PSNL
LISTED
NASDAQ
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale Cancer Center for a clinical trial titled “A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative brea...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
PSNL
LISTED
NASDAQ
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate that Personalis’ highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a strong predictor of outcomes in patients with stage I...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
PSNL
LISTED
NASDAQ
Personalis to Participate in Upcoming Investor Conferences
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the following conferences:
Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel in New York, NY
Lake Street 9th Annu...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
PSNL
LISTED
NASDAQ
Personalis to Announce Second Quarter 2025 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financia...
Themefolio
Profiler
Peergroup
© BusinessWire
18.07.2025
PSNL
LISTED
NASDAQ
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis’ new Vice President, Corporate Controller under Persona...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
09.07.2025
PSNL
LISTED
NASDAQ
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
News Preview
Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sens...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
PSNL
LISTED
NASDAQ
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demons...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
PSNL
LISTED
NASDAQ
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) respon...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
PSNL
LISTED
NASDAQ
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
PSNL
LISTED
NASDAQ
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN.
About Personalis, Inc.
At Personalis, we are transforming the active mana...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
PSNL
LISTED
NASDAQ
Personalis Reports First Quarter 2025 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights.
Recent Business Highlights
Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,44...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
PSNL
LISTED
NASDAQ
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing strong performance of its ultra-sensitive NeXT Personal assay in detecting early signs of residual or recurrent colorectal cancer (CRC).
The study, led by Dr. Jonathan Loree’s team at BC...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
PSNL
LISTED
NASDAQ
Personalis to Announce First Quarter 2025 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial re...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
PSNL
LISTED
NASDAQ
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company’s NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR)...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
PSNL
LISTED
NASDAQ
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough persona...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
PSNL
LISTED
NASDAQ
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
News Preview
Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
PSNL
LISTED
NASDAQ
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights.
Recent Business Highlights
Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compar...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
PSNL
LISTED
NASDAQ
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025, at the Boston Marriott Copley Place in Boston, MA.
About Personalis, Inc.
At Personalis, we are transforming the active manag...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
PSNL
LISTED
NASDAQ
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to di...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
PSNL
LISTED
NASDAQ
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 11, 2025, at The Cliff Lodge in Snowbird, UT.
About Personalis, Inc.
At Personalis, we are...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
PSNL
LISTED
NASDAQ
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
News Preview
Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
PSNL
LISTED
NASDAQ
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance.
Preliminary Full Year 2024 Revenue
Revenue of approximately $84.6 million for the full year of 2024 compared with $73.5 m...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
PSNL
LISTED
NASDAQ
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
News Preview
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
PSNL
LISTED
NASDAQ
Personalis and Tempus Expand Collaboration to Biopharma
News Preview
Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Te...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
PSNL
LISTED
NASDAQ
Personalis to Participate at Upcoming Investor Conferences
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences:
Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Fireside Chat Time: 12:30 pm Eastern Time
Location: The Lotte New York Palace in...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
PSNL
LISTED
NASDAQ
Personalis Reports Third Quarter 2024 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business accomplishments.
Recent Business Accomplishments
Raised approximately $35.0 million in net financing proceeds from Tempus AI, Inc. (Tempus), consisti...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
PSNL
LISTED
NASDAQ
Personalis to Present at the Stifel 2024 Healthcare Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, at 10:55 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel.
About Personalis, Inc.
At Personalis, we are transforming the...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
PSNL
LISTED
NASDAQ
Personalis to Announce Third Quarter 2024 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its finan...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
PSNL
LISTED
NASDAQ
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain. Personalis’ NeXT Personal assay was designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2024
PSNL
LISTED
NASDAQ
Personalis to Participate at Upcoming Investor Conferences
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Thursday, September 5, 2024
Presentation Time: 4:50 pm Eastern Time
Location: Marriott Marquis in N...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
PSNL
LISTED
NASDAQ
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on August 15, 2024, a non-qualified stock option to purchase an aggregate of 75,000 shares of its common stock to Personalis’ new Executive Director, Market Access & Reimburse...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
